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Abstract The National Institute for Health and Care
Excellence (NICE), as part of the institute’s single tech-
nology appraisal (STA) process, invited the manufacturer
of pomalidomide (POM; Imnovid, Celgene) to submit
evidence regarding the clinical and cost effectiveness of the
drug in combination with dexamethasone (POM ?
LoDEX) for the treatment of relapsed and refractory mul-
tiple myeloma (RRMM) after at least two regimens
including lenalidomide (LEN) and bortezomib (BOR).
Kleijnen Systematic Reviews Ltd (KSR) and Erasmus
University Rotterdam were commissioned as the Evidence
Review Group (ERG) for this submission. The ERG
reviewed the evidence submitted by the manufacturer,
validated the manufacturer’s decision analytic model, and
conducted exploratory analyses in order to assess the
robustness and validity of the presented clinical and cost-
effectiveness results. This paper describes the company
submission, the ERG assessment, and NICE’s subsequent
decisions. The company conducted a systematic review to
identify studies comparing POM with comparators outlined
in the NICE scope: panobinostat with bortezomib and
dexamethasone (PANO ? BOR ? DEX), bendamustine
with thalidomide and dexamethasone (BTD) and conven-
tional chemotherapy (CC). The main clinical effectiveness
evidence was obtained from MM-003, a randomized con-
trolled trial (RCT) comparing POM ? LoDEX with high-
dose dexamethasone (HiDEX; used as a proxy for CC).
Additional data from other studies were also used as non-
randomized observational data sources for the indirect
treatment comparison of POM ? LoDEX with BTD and
PANO ? BOR ? DEX. Covariate or treatment switching
adjustment methods were used for each comparison. The
model developed in Microsoft Excel 2010 using a semi-
Markov partitioned survival structure, submitted in the
original submission to NICE for TA338, was adapted for
the present assessment of the cost effectiveness of POM ?
LoDEX. Updated evidence from the clinical-effectiveness
part was used for the survival modelling of progression-
free survival and overall survival. For POM ? LoDEX, the
patient access scheme (PAS) discount was applied to the
POM price. Three separate comparisons were conducted
for each comparator, each comparison using a different
dataset and adjustment methods. The ERG identified and
corrected some errors, and the corrected incremental cost-
effectiveness ratios (ICERs) for POM ? LoDEX versus
each comparator were presented: approximately £45,000
per quality-adjusted life-year (QALY) gained versus BTD,
savings of approximately £143,000 per QALY lost versus
PANO ? BOR ? DEX, and approximately £49,000 per
QALY gained versus CC. The ERG also conducted full
incremental analyses, which revealed that CC, POM ?
LoDEX and PANO ? BOR ? DEX were on the cost-
effectiveness frontier. The committee’s decision on the
technology under analysis deemed that POM ? LoDEX
should be recommended as an option for treating multiple
myeloma in adults at third or subsequent relapse of treat-
ments including both LEN and BOR, contingent on the
company providing POM with the discount agreed in the
PAS.
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Key Points for Decision Makers
Non-randomized evidence can be used to assess
comparative effectiveness and inform cost-
effectiveness analyses in the absence of randomized
evidence. However, reviewers and decision makers
should pay special attention to the adjustment
methods used for accounting for differences between
patient populations at baseline as they may have
considerable impact on effectiveness and cost-
effectiveness results.
Treatment recommendations can be changed in time,
based on additional clinical and cost-effectiveness
evidence and changes in the clinical landscape, as
well as in prices.
Sometimes, the end-of-life criteria might not hold for
all of the comparators. In such a situation, the
decision maker might base the recommendation
according to the end-of-life threshold for the
comparisons that satisfy the end-of-life criteria. For
the other comparisons, the decision maker might
instead apply the standard threshold to the ICERs
calculated (e.g. ‘costs per QALY gained’ or ‘costs
saved per QALY lost).
1 Introduction
The National Institute for Health and Care Excellence
(NICE) is an independent organization providing national
guidance on promoting good health and preventing and
treating ill health [1]. The single technology appraisal
(STA) process is designed to provide recommendations on
a single product, device or other technology with a single
indication. The process covers new technologies and
enables NICE to produce guidance shortly after the tech-
nology is introduced into the UK. The NICE Appraisal
Committee (AC) obtains relevant evidence from several
sources: the company submission (CS), a report from the
appointed independent Evidence Review Group (ERG) and
advice from consultees (i.e. patients, experts and other
stakeholders). The CS includes a written report and a
decision analytic model that describes the clinical and cost
effectiveness of the technology under investigation. The
ERG, an external organization independent of the NICE,
reviews the CS and produces a summary report and pro-
vides a critique of the submitted evidence. After consid-
eration of all the relevant evidence, the AC formulates
preliminary guidance, in the form of the Appraisal Con-
sultation Document (ACD), as to whether or not to rec-
ommend the intervention. The stakeholders are invited to
comment on thisACD and the submitted evidence. A sub-
sequent ACD may be produced or a Final Appraisal
Determination (FAD) issued. Once published, NICE tech-
nology guidance provides a legal obligation for National
Health Service (NHS) providers to reimburse technologies
that have been approved. This paper presents a summary of
the ERG report and the development of NICE guidance
based on the findings of the AC for the STA of poma-
lidomide (POM) in combination with low-dose dexam-
ethasone (DEX), for treating relapsed and refractory
multiple myeloma (RRMM) after at least two regimens
including lenalidomide (LEN) and bortezomib (BOR). Full
details of all relevant appraisal documents can be found on
the NICE website [2.]
2 The Decision Problem
The underlying indication of this appraisal is RRMM.
Multiple myeloma is a rare, incurable malignant haema-
tological disease arising from the monoclonal expansion of
plasma cells in the bone marrow [3]. It represents
approximately 1% of all incident cancers globally and
results in more than 43,000 deaths annually worldwide.
Multiple myeloma is primarily a disease of the elderly, and
the median age at diagnosis ranges from 69 to 74 years
[4–6]. Patients suffer from a range of debilitating symp-
toms, including bone pain and damage including fractures,
mobility problems, anaemia and general ill health [7–9].
The course of the disease is characterised by cycles of
remission and relapse [10]. With increasing lines of ther-
apy, there is a decreasing duration of response and, ulti-
mately, development of refractory disease in combination
with greater symptomatic burden [10–12]. The main aims
of therapy are to control disease, maximise health-related
quality of life (HRQoL) and prolong survival [10–13].
Despite the availability of MM agents such as thalidomide
(THAL), BOR and LEN, prognosis remains bleak, espe-
cially for patients who relapse or are refractory to these
agents, with a median survival of 3–9 months [14–18.]
The clinical pathway of care for multiple myeloma
patients differs between transplant-eligible and transplant-
ineligible patients, especially in the choice of the first-line
therapy. For transplant-eligible patients, NICE guidance
TA311 recommends BOR ? DEX or BOR ? THAL ?
DEX induction therapy followed by autologous stem cell
transplant (ASCT) [19], whereas for transplant-ineligible
patients, THAL in combination with an alkylating agent
(e.g. melphalan) and a corticosteroid (e.g. prednisone) is
recommended. However, for THAL-contraindicated
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patients, THAL may be replaced with BOR (NICE guid-
ance TA228 [20]).
In the second line, BOR monotherapy is recommended
(TA129 [21]) as a treatment option for people who are at
their first relapse, with a patient access scheme (PAS). Note
that even though LEN is not recommended by NICE,
patients might have received LEN in the first two lines of
therapy as part of clinical trials, as well as through previous
funding from the Cancer Drugs Fund (CDF). From the third
line onwards, LEN ? DEX has been recommended with the
condition of a maximum of 26 cycles (TA171 [22]), while
PANO ? BOR ? DEX has been recommended as an option
for treating ‘‘adult patients with relapsed and/or refractory
multiple myeloma who have received C 2 prior regimens
including BOR and an immunomodulatory agent, when the
company provides PANO with the discount agreed in the
patient access scheme’’ (TA380) [23]. Besides the recom-
mended treatments above, conventional chemotherapy
(CC) and bendamustine (BEN) combinations (e.g. BEN in
combination with THAL and DEX-BTD) are commonly
used in UK clinical practice, with the latter being funded via
the CDF [24].
POM (Imnovid) is an oral immunomodulatory agent
for RRMM. POM in combination with DEX has a UK
marketing authorisation for the following indication: ‘‘po-
malidomide in combination with low dose dexamethasone
for the treatment of adult patients with relapsed and
refractory multiple myeloma who have received at least
two prior treatment regimens, including both lenalidomide
and bortezomib, and have demonstrated disease progres-
sion on the last therapy’’ [25].
Following a previous appraisal in 2015, NICE did not
recommend POM ? LoDEX within its market authorisa-
tion (TA338). The agent was re-evaluated in the current
submission following a new PAS price for the technology
and additional clinical and cost-effectiveness evidence.
The remit of this appraisal was specified by NICE’s final
scope [26], which was to assess the clinical and cost
effectiveness of POM ? LoDEX within its licensed indi-
cation. The proposed positioning of POM ? LoDEX is
from third-line treatment onwards. For patients who have
had two prior therapies, the comparators listed in the scope
were PANO ? BOR ? DEX, whereas for patients who
have had three or more prior therapies the comparators
were CC, BTD and PANO ? BOR ? DEX.
3 The Independent Evidence Review Group
(ERG) Report
Kleijnen Systematic Reviews Ltd (KSR), in collaboration
with Erasmus University Rotterdam, acted as the ERG, and
reviewed the evidence on the clinical and cost effectiveness
of POM ? LoDEX for the treatment of adult patients with
RRMM who have received at least two prior treatment
regimens, including both LEN and BOR, and have
demonstrated disease progression on the last therapy as
submitted by the company (Celgene).
The review embodied three aims:
• to assess whether the CS conformed to the method-
ological guidelines issued by NICE [1];
• to assess whether the company’s interpretation and
analysis of the evidence were appropriate;
• to indicate the presence of other sources of evidence or
alternative interpretations of the evidence that could
inform NICE guidance.
The ERG critically reviewed the evidence in the CS, in
the response to clarification questions, and evidence pro-
vided after publication of the ACD. Furthermore, it con-
ducted additional searches, explored the impact of
assumptions on the incremental cost-effectiveness ratio
(ICER), revised the economic model and explored addi-
tional scenario analyses.
3.1 Summary of the Clinical Evidence
The company conducted a systematic review to inform the
submission. The main direct evidence was taken from the
MM-003 randomised controlled trial, which was the only
trial that compared POM ? LoDEX with any of the
comparators listed in the final scope (i.e. HiDEX; used as a
proxy for CC). Individual patient data (IPD) from patients
receiving POM ? LoDEX in the MM-002, MM-003 and
MM-010 studies, and from the MUK-One [27], Gooding
et al. [15] and Tarant et al. [16] studies of BEN formed the
source of the comparison between POM ? LoDEX and
BTD. For the comparison of POM ? LoDEX versus PANO
? BOR ? DEX, IPD from the POM ? LoDEX arms of the
MM-003 [28], MM-002 [29] and MM-010 [30] studies, as
well as the aggregate data from the single-arm PANOR-
AMA-2 study, were used. An overview of the trials used
can be seen in Table 1.
3.1.1 Direct Evidence
The MM-003 randomised controlled trial was the only
study that directly compared POM ? LoDEX with any of
the comparators listed in the final scope [26]. This trial
compared POM ? LoDEX (POM 4 mg/day on days 1–21
and DEX 40 mg each week in a 4-week cycle) with high-
dose dexamethasone (HiDEX; DEX 40 mg on days 1–4,
9–12 and 17–20 of a 4-week cycle). The company con-
sidered HiDEX as a proxy for CC. MM-003 included 455
participants and was an open-label, multinational trial
including participants recruited in 93 study sites, 68 of
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which are located in Europe. The number of centres located
in the UK and number of patients recruited in the UK was
unclear.
Using the latest data cut-off of MM-003 (1 September
2013, investigator assessment) at 15.4 months follow-up,
there was an increase in median survival with pomalido-
mide. Overall survival (OS) was significantly better for
patients treated with POM ? LoDEX compared with those
receiving HiDEX [13.1 months vs. 8.1 months; hazard
ratio (HR) 0.72, 95% confidence interval (CI) 0.56–0.92].
POM ? LoDEX significantly extended progression-free
survival (PFS) compared with HiDEX (4 vs. 1.9 months;
HR 0.50, 95% CI 0.41–0.62).
Since 56% of patients in the HiDEX arm received
subsequent therapy with POM in the MM-003 trial, the
company provided crossover-adjusted OS results, which
are given in Table 2.
The company found that 247 of 300 patients (82.3%) in
the POM ? LoDEX group had at least one adverse event
(AE) considered by the investigator to be related to POM.
Furthermore, 190 patients (63.3%) had grade 3–4 treat-
ment-emergent AEs (TEAEs) considered to be related to
POM. However, the company stated that ‘‘with dose
modifications and supportive care the safety profile was
predictable, manageable and generally well tolerated’’.
Events occurring more frequently in the POM ? LoDEX
group included neutropenia (51.3 vs. 20.0% for neutrope-
nia and 9.3 vs. 0% for febrile neutropenia). The main cause
of treatment discontinuation was progressive disease, and
discontinuations related to AEs were uncommon. There
were more dose interruptions in the POM ? LoDEX group
than in the HiDEX group (67 vs. 30%).
3.1.2 Indirect Evidence
No studies directly compared POM ? LoDEX with either
BEN or PANO ? BOR ? DEX. Furthermore, no studies
could provide a common comparator to support an indirect
comparison or mixed treatment comparison (MTC). As a
consequence, the company selected individual treatment
arms from the available studies and performed separate
analyses comparing POM ? LoDEX with each of the
comparators independently.
3.1.2.1 Indirect Comparison with Bendamustine Com-
parison of IPD from patients receiving POM ? LoDEX in
Table 1 Eligible studies included in the quantitative analysis
Intervention Study IPD Description
POM ? LoDEX MM-003 [28] Available Phase III, RCT (n = 455, 2:1) comparing POM ? LoDEX vs. HiDEX in RRMM patients
MM-002 [29] Available Phase II, RCT (n = 221, 1:1) comparing POM ? LoDEX vs. POM in RRMM patients
MM-010 [30] Available Phase IIIb, single-arm (n = 682), open-label study of POM ? LoDEX in RRMM patients
BEN MUK-One
[27]
Available RCT (n = 95) comparing different doses of BEN (100 mg/m2 vs. 60 mg/m2) of two BTD
regimens applied to RRMM patients
Tarant et al.
[16]
Available Retrospective study (n = 55) on the effectiveness and safety of various therapies
(including BTD) in RRMM patients
Gooding et al.
[15]
Available Retrospective study (n = 39) on the effectiveness and safety of various therapies
(including BTD) in RRMM patients
PANO?BOR?DEX PANORAMA-
2 [31]
Not
available
Two-stage, single-arm, open-label study (n = 55) on the effectiveness and safety of PANO
? BOR ? DEX in RRMM patients
POM pomalidomide, LoDEX low-dose dexamethasone, BEN bendamustine, PANO panobinostat, BOR bortezomib, DEX dexamethasone, RCT
randomised controlled trial, RRMM relapsed and refractory multiple myeloma, BTD bendamustine ? thalidomide ? dexamethasone, IPD
individual patient-level data, HiDEX high-dose dexamethasone
Table 2 Intention-to-treat and crossover-adjusted OS results from MM-003 trial
Median OS in months POM ? LoDEX (95% CI) HiDEX (95% CI) Difference (HR, 95% CI)
Intent-to-treat, (independent assessment, earlier data cut) 12.7 (10.4–15.5) 8.1 (6.9–10.8) 4.6 (0.74, 0.56–0.97)
Crossover adjustment, two-stage method 12.7 (10.4–15.5) 5.7 (4.2–7.5) 7.0 (0.52, 0.39–0.68)
Crossover adjustment, RPSFTM method 12.7 (10.4–15.5) 6.7 (4.6–10.5) 6.0 (HR 0.49, 0.33–1.00)
Source: Company submission, Table 24 (page 75) [32]
OS overall survival, POM pomalidomide, LoDEX low-dose dexamethasone, HiDEX high-dose dexamethasone, HR hazard ratio, RPSFTM rank-
preserving structural failure time model, CI confidence interval
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the MM-002 [29], MM-003 [28] and MM-010 [30] studies
with IPD from the MUK-One [27], Gooding et al. [15] and
Tarant et al. [16] studies of BTD was achieved using Cox
proportional hazards regression models to adjust for factors
thought to be prognostic of OS and PFS (based on mean
covariate values according to the baseline of the pooled
trials). The prognostic factors to be included in the
regression model in the CS were determined according to a
selection procedure based on data availability, information
derived from the systematic literature review of prognostic
factors in RRMM and clinical expert consultation. Fol-
lowing the selection procedure, the CS reported the fol-
lowing covariates in the final analysis given in Table 3.
The MM-002 trial [29] alone was selected for use for
POM ? LoDEX within the base-case analysis due to the
lower levels of refractoriness exhibited within this trial
(78%) compared with the remainder of the POM ? LoDEX
data (95%). This lower level of refractoriness was con-
sidered more comparable with the BTD data (18–25%
across sources). As this covariate was identified by clini-
cians as the most important prognostic factor and is diffi-
cult to adjust for with the current datasets (given that the
overlap between datasets is low), it was considered more
important to select the more comparable dataset for anal-
ysis than to retain the maximum number of patients for
analysis in the POM ? LoDEX arm.
The company conducted three sensitivity analysis. In the
first sensitivity analysis, the company incorporated data
from all available POM ? LoDEX trials (MM-002 [29],
MM-003 [28] and MM-010 [30]), while in the second
sensitivity analysis, the company incorporated Interna-
tional Staging System (ISS) stage as an additional covari-
ate, on the dataset that includes patients whose ISS stage
was available (i.e. the MM-002 [29] and Gooding et al
[15.] studies were excluded). The last sensitivity analysis
was conducted on the same dataset used in sensitivity
analysis 2, but this time ISS stage was not included as a
covariate. The unadjusted and covariate-adjusted results
from the base-case analysis and sensitivity analyses are
given in Table 4.
From the results of the base-case and sensitivity analy-
ses, the company concluded that POM ? LoDEX improves
OS and PFS compared with BTD, and the inclusion of
POM ? LoDEX data from the MM-003 [28] and MM-010
[30] trials did not substantially alter the results of the PFS,
whereas it reduced the OS benefit of POM ? LoDEX
compared with the base-case. Furthermore, the company
suggested that, based on the results of sensitivity analyses 2
and 3, even though ISS stage is a very important predictive
factor of an increased hazard of death and progression, it
had little impact on the HR of PFS and OS.
3.1.2.2 Indirect Comparison with PANO ? BOR ? DEX
For the comparison of POM ? LoDEX versus PANO ?
BOR ? DEX, IPD from the POM ? LoDEX arms of the
MM-003 [28], MM-002 [29] and MM-010 [30] studies, as
well as the aggregate data from the single-arm PANOR-
AMA-2 study [31], were used. For this comparison, not all
patients in the POM ? LoDEX trials, but a subgroup
(n = 886), who were refractory to BOR but not primary
refractory, was included to align with the PANORAMA-2
population. Since no IPD were available from the
PANORAMA-2 study publication [31], covariate adjust-
ment methods used in the comparison with BTD were not
possible, and the company used the matching-adjusted
indirect comparison (MAIC) method to adjust for the dif-
ferences in patient characteristics between studies. The
MAIC method reweights the patient-level data for POM ?
LoDEX to reflect a population of similar baseline charac-
teristics as the PANO ? BOR ? DEX population. The
results from the unadjusted and MAIC-adjusted analysis
are given in Table 5.
As can be seen, the application of the MAIC method
resulted in a 1-month increase in median OS for patients
receiving POM ? LoDEX compared with the unweighted
analysis, and, in both cases, the median OS was shorter
than the median OS of patients receiving PANO ? BOR ?
DEX. The application of MAIC seems to have little effect
on the median PFS of patients treated with POM ? LoDEX
compared with the unweighted analysis. These results
suggest that POM ? LoDEX reduced the risk of
Table 3 Covariates used in the
BTD vs. POM ? LoDEX
indirect comparison
Covariate Type (e.g. continuous/categorical)
Treatment arm Categorical (POM ? LoDEX or BTD)
Age at the start of the treatment Continuous
Number of prior treatment lines of therapy Continuous
Receipt of prior THAL Categorical (yes/no)
Refractory to LEN Categorical (yes/no)
ISS stage (in sensitivity analyses) Categorical (1/2/3)
THAL thalidomide, LEN lenalidomide, ISS International Staging System, POM pomalidomide, LoDEX low-
dose dexamethasone, BTD bendamustine ? thalidomide ? dexamethasone
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progression but increased the risk of death compared with
PANO ? BOR ? DEX; however, the company noted that
the differences were not statistically significant and the
evidence for PANO ? BOR ? DEX was based on only 55
patients compared with 886 patients receiving POM ?
LoDEX.
3.1.3 End of Life
The company stated that POM ? LoDEX is considered to
meet the NICE end-of-life criteria in comparison with BEN
and CC. They stated that ‘‘The estimated survival benefit
compared to BEN and conventional chemotherapy is[ 5
months in all comparisons (covariate adjusted and unad-
justed, crossover adjusted and unadjusted). Modelled mean
survival increase is 7–8 months’’.
They further stated that in relation to PANO ‘‘Evidence
for end of life is less compelling in the comparison to
PANO ? BOR ? DEX as no improvement was demon-
strated in median outcomes for OS; difficulties in com-
paring to PANO ? BOR ? DEX are, however,
considerable given the limited evidence available and lack
of patient level data to correct for differences in patient
population’’.
3.2 Critique of the Clinical Evidence
The systematic reviews conducted by the company (for
both the clinical studies and the prognostic covariate
selection procedure) were deemed appropriate to the scope
Table 4 Summary results (OS, PFS) from the POM ? LoDEX vs. BTD comparison
Analysis (trial data used in the dataset) OS PFS, in months (95% CI)
Unadjusted Adjusted Unadjusted Adjusted
Base-case (MM-002 [29], MUK-One [27], Gooding
et al. [15], Tarant et al. [16])
Median, in
months
(95% CI)
POM ? LoDEX:
16.5 (12.6–19.8)
BTD: 8.1
(5.3–15.5)
POM ?
LoDEX: 16.6
(12.6–21.3)
BTD: 10.5
(5.8–14.8)
POM ?
LoDEX: 4.2
(3.7–5.8)
BTD: 3.3
(2.5–5.5)
POM ?
LoDEX: 4.7
(3.7–6.6)
BTD: 3.7
(2.8–5.6)
HR
(95% CI)
0.55 (0.38–0.81) 0.58
(0.36–0.94)
0.76
(0.56–1.05)
0.79
(0.52–1.22)
Sensitivity analysis 1 (MM-002 [29], MM-003 [28],
MM-010 [30], MUK-One [27], Gooding et al. [15],
Tarant et al. [16])
Median, in
months
(95% CI)
POM ? LoDEX:
12.6 (11.6–13.8)
BTD: 8.1
(5.3–15.5)
POM ?
LoDEX: 12.7
(11.9–13.9)
BTD: 8.1
(6.1–12.4)
POM ?
LoDEX: 4.3
(3.9–4.7)
BTD: 3.3
(2.5–5.5)
POM ?
LoDEX: 4.6
(3.9–4.8)
BTD: 2.8
(2.2–3.8)
HR (95%
CI)
0.68 (0.51–0.92) 0.64
(0.45–0.91)
0.80
(0.62–1.03)
0.61
(0.45–0.84)
Sensitivity analysis 2 (MM-003 [28], MM-010 [30],
MUK-One [27], Tarant et al. [16])
HR (95%
CI)
NR 0.72
(0.47–1.11)
NR 0.62
(0.43–0.90)
Sensitivity analysis 3 (MM-003 [28], MM-010 [30],
MUK-One [27], Tarant et al. [16])
HR (95%
CI)
NR 0.82
(0.54–1.27)
NR 0.62
(0.43–0.89)
OS overall survival, PFS progression-free survival, POM pomalidomide, LoDEX low-dose dexamethasone, CI confidence interval, HR hazard
ratio, BTD bendamustine ? thalidomide ? dexamethasone, NR not reached
Table 5 Summary results (OS, PFS) from the POM ? LoDEX vs.
PANO ? BOR ? DEX comparison
POM ? LoDEX PANO ? BOR ? DEX
OS
Median OS, months (95% CI)
Unweighted
Weighted
12.4 (11.1–13.4)
13.4 (11.4–15.6)
17.5 (10.8–22.22)
NA
HR (95% CI)
Unweighted
Weighted
0.73 (0.52–1.02)
0.78 (0.56–1.09)
PFS
Median PFS, months (95% CI)
Unweighted
Weighted
4.1 (3.7–4.6)
4.2 (3.7–4.8)
5.3 (3.9–6.6)
NA
HR (95% CI)
Unweighted
Weighted
1.12 (0.85–1.48)
1.18 (0.89–1.56)
Source: Evidence Review Group report, Table 4.27 (page 85) [33]
POM pomalidomide, LoDEX low-dose dexamethasone, PANO
panobinostat, BOR bortezomib, DEX dexamethasone, OS overall
survival, PFS progression-free survival, HR hazard ratio, CI confi-
dence interval, NA not available
150 N. C. Bu¨yu¨kkaramikli et al.
of the submission. Although the ERG identified a number
of problems in relation to searching for studies of clinical
effectiveness, it was satisfied that the evidence presented in
the submission was the best available in this limited area.
The ERG agreed that a meta-analysis could not have been
conducted as only one trial was deemed directly relevant to
the decision problem (MM-003).
Although MM-003, the main trial forming the direct
evidence for pomalidomide, was a reasonably large, well-
conducted, multicentre trial, the main comparator (HiDEX)
is no longer optimal in current practice; therefore, the
comparator can only be viewed as a proxy for CC. Addi-
tionally, over 50% of patients in the trial were aged
65 years or under, therefore may reflect a younger popu-
lation than that typically seen in practice. The ERG noted
an underrepresentation of non-White participants. Under
1% were of Asian origin and 1.5% were of Black or
African American origin. The trial was in a heavily treated
population who had received a median of five therapies
(range 2–17). Results were presented for only 17 patients
receiving two prior therapies, thus the trial is not repre-
sentative of POM ? LoDEX as a third-line therapy. Within
these constraints, POM ? LoDEX appears to extend OS
and PFS in comparison with HiDEX in a heavily treated
population who are refractory to BOR and LEN. The AE
profile appears to be manageable with appropriate dose
reductions and interruptions. However, the slightly higher
incidence of serious AEs (grade 3 and 4) attributed to POM
? LoDEX was drawn to the attention of the committee,
along with the more frequent occurrence of neutropenia.
No studies directly compared POM ? LoDEX with
either BTD or PANO ? BOR ? DEX. In addition, the
available studies did not include a common comparator that
would permit an indirect treatment comparison or MTC. As
a result, the company presented evidence based on indirect
comparisons. The ERG noted that the covariate adjusted
results were very similar to the unadjusted results in terms
of both PFS and OS for the base-case and the sensitivity
analysis of POM ? LoDEX compared with BTD, indi-
cating that the differences between studies in the selected
covariates (patient characteristics) have relatively little
impact on the outcomes observed. The selection of dif-
ferent datasets for POM ? LoDEX alters the results for OS.
Results suggested that the survival benefit of POM ?
LoDEX was less for patients in the MM-003 and MM-010
studies than for patients in the MM-002 study of POM. The
ERG is doubtful about the exclusion of the MM-003 and
MM-010 trials in the base-case analysis of the BTD versus
POM ? LoDEX comparison on the basis of higher LEN
refractoriness (approximately 20% in BTD trials, 78% in
MM-002 and 95% in MM-003 and MM-010).
For the comparison with PANO ? BOR ? DEX, as in
the comparison with BTD, the matching adjustment did not
substantially alter the results. This implies that the differ-
ences between studies in the selected covariates have rel-
atively little impact on the outcomes observed. The ERG
noted that the number of patients receiving PANO ? BOR
? DEX was small (n = 55) and there were some differ-
ences between POM studies and PANORAMA-2 in terms
of the number of prior lines of therapy.
The ERG recognised that the lack of all patient-level
data might have excluded many of the standard alterna-
tives/methodologies used in the indirect comparison of
non-randomised data. However, the ERG considered that
some of the choices (e.g. adjustment methods as well as
datasets included) were rather arbitrary and the company
could have followed a more systematic approach (e.g.
following the recommendations in NICE DSU TSD 17 and
TSD 18 [34]). Furthermore, there can be unmeasured
confounding factors, which could have been quantitatively
assessed.
In terms of the end-of-life criteria, the ERG agrees that
the patient group, being at least at the third line of treat-
ment for RRMM, have a short life expectancy, normally\
24 months. Hence, the first criterion for end of life has been
met. As regard the second criteria, the ERG agrees that
POM ? LoDEX appear to meet end-of-life criteria of
increasing survival in relation to BTD and DEX; however,
the evidence suggests that POM ? LoDEX does not meet
this criterion compared with PANO ? BOR ? DEX. It is
noted though that the evidence for PANO ? BOR ? DEX
is based on a small number of patients (n = 55) and the
analysis was limited by the lack of studies comparing these
treatments.
3.3 Summary of the Cost-Effectiveness Evidence
The company performed an update of the systematic
review of cost-effectiveness studies and evidence on
healthcare resource use and HRQoL. Furthermore, the key
issues raised by the committee from the previous appraisal
(TA338) were extracted and are summarised in Table 6.
An electronic model was developed in Microsoft Excel
2010 (Microsoft Corporation, Redmond, WA, USA) using
a semi-Markov partitioned survival structure. The objective
of the model was to estimate the cost effectiveness of POM
? LoDEX when compared with BTD, PANO ? BOR ?
DEX and CC for the treatment of patients with RRMM
who were previously treated with LEN and BOR and
whose disease progressed during the last therapy.
The model structure presented four health states: a pre-
progressive state split into ‘on-treatment’ and ‘off-treat-
ment’, a post-progression state (progressive disease), and
death. The cycle length of the model was 1 week and the
time horizon was 15 years (i.e. lifetime, since virtually
every patient in the model died within 15 years). The
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model considered an NHS and personal social services
perspective, and costs and utilities were discounted using a
yearly rate of 3.5%.
The transition probabilities between health states were
estimated from the parametric survival functions fitted to
OS, PFS and time to treatment discontinuation (TTD) data
from the relevant data sources. The data sources and
methodological approaches for covariate adjustment for
each comparison are summarized in Table 7.
Seven parametric distributions (exponential, log-normal,
log-logistic, Gompertz, gamma, extreme value and Wei-
bull) were examined for each clinical outcome (OS, PFS
and TTD). The fit of each covariate-adjusted parametric
model to the Kaplan–Meier survival data was explored
using visual inspection, log-cumulative hazard and Q–Q
plots, Akaike/Bayesian information criterion (AIC/BIC)
goodness-of-fit statistics and clinical plausibility. In
Table 8, the survival analysis methods and the curves
chosen for the base-case are summarized.
TEAEs of grade 3/4 were included in the economic
model based on a 2% occurrence threshold in the MM-003
trial dataset. For BTD and PANO ? BOR ? DEX, in the
base-case, the AE rates of POM ? LoDEX were multiplied
by risk ratios for treatment discontinuation due to a TEAE
(under the comparator vs. under POM ? LoDEX). In a
scenario analysis, instead of risk ratios, safety scores pro-
vided by an advisory board were used.
Utilities for each health state were found using a
regression model based on EQ-5D data from the MM-003
trial. While many covariates were assumed to be the same
between treatments, treatment-specific utilities were
obtained by using treatment-specific values for the fol-
lowing covariates: disease progression, best overall
response (applied after week 12, maintained lifelong),
hospitalisations and AEs. Furthermore, a utility decrement
of 0.025 (based on two previous STAs on lung cancer
treatments [36, 37]) was applied for patients receiving
subcutaneous or intravenous treatments in the base-case.
The drug acquisition costs of BTD, PANO ? BOR ?
DEX and CC treatments were based on list prices. For CC,
cyclophosphamide in combination with THAL ? DEX was
assumed to reflect the UK practice. A PAS price discount
agreement was available for POM ? LoDEX. In addition,
for pomalidomide, cost savings due to less drug use from
dose interruptions longer than 28 days were incorporated.
A questionnaire completed by six clinical specialists was
used to collect data on monitoring, concomitant medication
and AE costs. End-of-life cost estimates from a UK study
were used [38]. Costs associated with intravenous and
subcutaneous administration visits were based on the
TA311 appraisal for BOR in first-line MM therapy [19]. In
the base-case, no subsequent therapies were included fol-
lowing treatment discontinuation, but the impact of this
assumption was explored in a scenario analysis based on
Table 6 List of issues raised by the committee in TA338 and the company’s description on how these issues are addressed in the current
company submission
Issues in TA338 How the issue is addressed in the current submission,
according to the company
Comparative
effectiveness data
Very few data were identified for current care Updated data [i.e. MUK-One study, Gooding et al. study
and Tarant et al. study (to inform comparison with BTD)
and PANORAMA-2 (to inform comparison with PANO
? BOR ? DEX)]
Assumptions
regarding
equivalence of
comparators
Assumption of equal effectiveness among all comparators Comparator-specific data provided to inform comparison
with BTD and PANO ? BOR ? DEX
Relative benefit of
current care vs.
HiDEX
Concerns around the survival predictions for the current
care (lower survival than for HiDEX, which was
considered suboptimal treatment)
This unexpected result was no longer seen
Adjustment of trials
to provide
comparable
estimates
Differences between the populations in the studies
included for analysis in TA338
Adjustments for differences in patient characteristics were
conducted based on a covariate selection process
Adverse events Cut-off point to include disutility values only for AEs that
occurred in more than 2% of patients
No change
Dosing Exclusion of costs of unused tablets (not necessarily entire
pack) of POM ? LoDEX due to non-protocol
interruptions
Only dose interruptions that would result in an entire pack
not being used are assumed not to incur costs
POM pomalidomide, LoDEX low-dose dexamethasone, PANO panobinostat, BOR bortezomib, DEX dexamethasone, BTD bendamustine ?
thalidomide ? dexamethasone, AEs adverse events, HiDEX high-dose dexamethasone
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Table 7 Data sources and methodological approaches for covariate/crossover adjustments for each comparison
POM ? LoDEX vs. BTD POM ? LoDEX vs.
PANO ? BOR ? DEXa
POM ? LoDEX vs. CC
Data source
used in
covariate
adjustment
IPD from MM-002, Gooding et al., Tarant et al.
and MUK-One
IPD from a subset of
MM-002, MM-003 and
MM-010
Summary data and pseudo
patient-level data from
PANORAMA-2
MM-003 (HiDEX used as a proxy)
Covariates
included for
the
adjustment
Age
Prior lines of therapy
Refractoriness to LEN
Receipt of prior THAL
Age
Prior lines of therapy
Receipt of prior THAL
ECOG status
Not required—within trial comparison
Adjustment
method
CGP in the base-case and mean covariates
methods for the scenario analysis, both
methods described in Ghali et al. [35]
Matching-adjusted
indirect comparison
(MAIC)
Two-stage OS crossover adjustment for
patients in the HiDEX arm who received
POM ? LoDEX after progression
POM pomalidomide, LoDEX low-dose dexamethasone, PANO panobinostat, BOR bortezomib, DEX dexamethasone, OS overall survival, PFS
progression-free survival, BTD bendamustine ? thalidomide ? dexamethasone, IPD individual patient-level data, THAL thalidomide, LEN
lenalidomide, CGP corrected group prognostics, CC conventional chemotherapy, HR hazard ratio, ECOG Eastern Cooperative Oncology Group,
MAIC matching-adjusted indirect comparison, HiDex high-dose dexamethasone
aThe PANO ? BOR ? DEX vs. POM ? LoDEX PFS/OS HRs found from the MAIC method was applied on the POM ? LoDEX curve that was
derived from the CGP method conducted on MM-002, MM-003, MM-010 and all BTD trial data
Table 8 Survival analysis methods and curves chosen in the base-case for each comparison
POM ? LoDEX vs. BTD POM ? LoDEX vs. PANO ? BOR ? DEX POM ? LoDEX vs. CC
OS Exponential distribution-based curves with
baseline characteristics as covariates used
for the joint modelling (i.e. for both POM
? LoDEX and BTD) of OS data from the
MM-002, MUK-ONE, Gooding et al. and
Tarant et al. trials
For POM ? LoDEX: generalised gamma
distribution-based curve with baseline
characteristics as covariates used for the
extrapolation of OS data from the MM-
002, MM-003, MM-010, MUK-ONE,
Gooding et al. and Tarant et al. trials.
Then, for PANO ? BOR ? DEX, the OS
HR derived from MAIC was applied on
that POM ? LoDEX OS curve
Exponential distribution-based curves
adjusted using two-stage Weibull
approach for treatment switching were
used for the joint modelling (i.e. for both
POM ? LoDEX and CC) of OS data from
MM-003 trial
PFS Generalized gamma distribution-based
curves with baseline characteristics as
covariates used for the joint modelling
(i.e. for both POM ? LoDEX and BTD)
of PFS data from the MM-002, MUK-
ONE, Gooding et al. and Tarant et al.
trials
For POM ? LoDEX: generalised gamma
distribution-based curve with baseline
characteristics as covariates used for the
extrapolation of PFS data from the MM-
002, MM-003, MM-010, MUK-ONE,
Gooding et al. and Tarant et al. trials.
Then, for PANO ? BOR ? DEX, the PFS
HR derived from MAIC was applied on
that POM ? LoDEX PFS curve
Generalised gamma distribution-based
curves were used for the joint modelling
(i.e. for both POM ? LoDEX and CC) of
PFS data from the MM-003 trial
TTD A common treatment effect based on the
MM-002 and BTD trials applied to PFS
generalized gamma curves
A common treatment effect based on the
MM-002, MM-003, MM-010 and BTD
trials was applied to the PFS generalized
gamma curve for POM ? LoDEX. No
modelling for TTD of PANO ? BOR ?
DEX treatment as they receive a fixed
dose regimen
Extreme value distribution-based curves
were used for the individual modelling
(i.e. for POM ? LoDEX and CC
separately) of the TTD data from the MM-
003 trial
POM pomalidomide, LoDEX low-dose dexamethasone, PANO panobinostat, BOR bortezomib, DEX dexamethasone, OS overall survival, PFS
progression-free survival, BTD bendamustine ? thalidomide ? dexamethasone, CC conventional chemotherapy, TTD time to treatment dis-
continuation, HR hazard ratio, MAIC matching-adjusted indirect comparison
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Haematological Malignancy Research Network registry
data [4, 39]. All costs used in the model calculations were
based on their 2015 (original or inflation-corrected) values.
The company did not provide a full incremental analysis
including all comparators. Instead ICERs of POM ?
LoDEX versus each comparator were presented: £39,665
per quality-adjusted life-year (QALY) gained (vs. BTD),
£141,793 savings per QALY lost—southwest quadrant (vs.
PANO ? BOR ? DEX), and £44,811 per QALY gained
(vs. CC).
Probabilistic analysis that included parametric uncer-
tainty as well as structural uncertainty around the fitted
curve distribution choice, generated similar mean ICERs
and indicated the following probabilities of cost effec-
tiveness of POM?LoDEX for each comparison: 92.8%
versus BTD, 100% versus PANO?BOR?DEX (at list
price for PANO), and 56.9% versus CC at a willingness-to-
pay threshold of £50,000 per QALY gained.
The one-way sensitivity analyses showed that the
parameters with the greatest impact on the outcomes were
the coefficients used within the utility regression analysis
for the comparison against BTD and CC, and the MAIC
HRs (OS and PFS) for the comparison with PANO ? BOR
? DEX. The model is relatively insensitive to the majority
of other parameters.
The scenario analyses demonstrated that for the com-
parison with BTD, time horizon, choice of dataset (e.g.
MM-002, MM-003 and MM-010) and assumptions sur-
rounding subsequent therapy, administration and AE costs
had considerable impact on the ICER. For the PANO ?
BOR ? DEX comparison, time horizon, OS/PFS curve
distribution choices and the covariate adjustment method
were the most influential on the ICER. Finally, for the
comparison with CC, choice of the OS/PFS curve distri-
bution and the method for the crossover adjustments had
the biggest impact on the ICER.
3.4 Critique of the Cost-Effectiveness Evidence
The searches and economic model were considered by the
ERG to meet the NICE reference case; however, in the
final scope, NICE requested that at third line only PANO ?
BOR ? DEX, and at later lines all comparators (BTD,
PANO ? BOR ? DEX and CC), should have been con-
sidered. This line-based comparator stratification could not
be achieved due to the lack of data.
In the CS base-case, a different dataset was used for
each of the three comparisons, which implied that each
comparison was based on a slightly different population.
The ERG considered that an assessment based on a fully
incremental analysis (e.g. an analysis that involves the
calculation of incremental QALY gains and costs along all
treatment options ranked by ascending cost), using the
same dataset (MM-002, MM-003, MM-010 and all BTD
trials) for the POM ? LoDEX PFS/OS estimates and
applying the MAIC-based PFS/OS HRs for the PANO ?
BOR ? DEX comparison and PFS HR and crossover-ad-
justed OS HR from the MM-003 trial for the CC com-
parison, might have been more consistent.
In general, the process for extrapolating survival curves
was in line with the NICE DSU 14 guideline [40]. How-
ever, it was not clear how the visual fit has been assessed
(i.e. it seemed as if the covariates of the parametric survival
curves were adjusted according to the baseline of the
pooled trials, whereas treatment-specific baselines might
have been more appropriate for visual fit). Furthermore, the
ERG noted that different baselines were assumed in the
corrected group prognosis (CGP) method (baseline from
the pooled trial datasets) and in the mean covariates
method (baseline representing UK clinical practice).
Similarly, the ERG had some concerns related to the
implementation of AEs. The followed approach would
mirror the frequency order of the AEs of POM ? LoDEX
(MM-003 trial) for each of the comparators, in the same
magnitude. The ERG considered this assumption not to be
plausible because each drug has a different working
mechanism and different safety profiles, and it is unlikely
that the AE frequency order would be mirrored for other
comparators in the same magnitude.
The ERG did not encounter major issues with the
approach used to include quality of life in the model.
Nevertheless, the data and the assumptions about the
covariates that are included in the utility regression model
(e.g. best overall response rate, hospitalisation and AEs)
might lead to bias in utility estimates (e.g. assuming the
same hospitalisation rate from the HiDEX arm of the MM-
003 trial for all comparators, inconsistencies within the
categorisation of best overall response rate among different
comparators, and the uncertainty around the disutility
associated with intravenous/subcutaneous treatments).
The current submission re-estimated some of the
resource use inputs compared with TA338 (e.g. monitoring
costs were based on an extensive questionnaire completed
by six clinical experts). The ERG considered that the input
parameters derived from the resource use questionnaire
should be considered with care due to the low number of
experts (n = 6) who completed the questionnaire, as well
as the length and level of detail of the questionnaire, which
might have provided a challenge to fill in all fields with the
required attention. Furthermore, the model allowed for a
decrease in drug acquisition costs based on treatment
interruptions lasting longer than 28 days only for POM and
panobinostat, whereas the dose interruptions of BOR
(within PANO ? BOR ? DEX), BTD and CC were not
taken into account at all, creating a potential inconsistency.
Finally, regarding the costs of subsequent treatment, the
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ERG does not agree with the base-case choice of excluding
these costs. Since the effects of the subsequent treatments
were implicitly incorporated into the OS results, it would
be rational to also include the costs required to achieve
those effects. The CS provided two cost estimates for the
subsequent treatments to be used in scenario analyses.
These estimates differed greatly, and the information on
them was insufficient for the ERG to judge which estimate
was better to use.
3.5 Additional Exploratory Analyses Conducted
by the ERG
In the original CS model, the ERG identified some pro-
gramming errors. After these errors were corrected, the
base-case analyses of the company were repeated with the
ERG-corrected model. The ICER results were approxi-
mately £45,000 per QALY gained for POM ? LoDEX
versus BTD, £143,000 savings per QALY lost for POM ?
LoDEX versus PANO ? BOR ? DEX—southwest quad-
rant—and £49,000 per QALY gained for POM ? LoDEX
versus CC.
The ERG then conducted a list of exploratory full-in-
cremental analyses in which the effectiveness of BTD and
POM ? LoDEX treatments were based on the pooled
dataset of MM-002, MM-003, MM-010 and all other BTD
trials. In the first analysis, the CGP method was used for
the covariate adjustment and POM ? LoDEX and BTD OS
and PFS curves were generated. For PANO ? BOR ?
DEX, the HRs obtained from the MAIC were applied on
top of the POM ? LoDEX curves; and, similarly for CC,
the HRs from the intention-to-treat analysis of the OS and
PFS data from the MM-003 trial were applied on top of the
POM ? LoDEX curves. The second full-incremental
analysis had the same assumptions as the first full incre-
mental analysis, except the OS HR from the MM-003 trial
that was applied on top of the POM ? LoDEX curve was
corrected for the treatment switching using a two-stage
method. Finally, in the third full incremental analysis, for
generating POM ? LoDEX and BTD curves, the mean
covariate adjustment method was used (not using the
baseline of the pooled trials but a baseline reflecting real-
world data from UK centres) instead of the CGP method.
The results of these full incremental analyses (with list
prices for panobinostat) are provided in Table 9.
In all of these exploratory analyses, CC, POM ? LoDEX
and PANO ? BOR ? DEX were on the cost-effectiveness
frontier. POM ? LoDEX seems to be cost effective in
comparison with PANO ? BOR ? DEX, however the cost
effectiveness of POM ? LoDEX versus CC was dependent
on underlying assumptions of the analyses.
Furthermore, in several scenario analyses, the ERG
explored the uncertainty surrounding the assumptions on
dose interruptions, subsequent treatment costs, wastage
drug costs, utility regression model inputs, AE rates and
other utility estimates. The ICER results were more or less
similar across these analyses. Finally, the ERG imple-
mented the confidential PAS price for PANO ? BOR ?
DEX, which decreased the ICER of PANO ? BOR ? DEX
versus POM ? LoDEX comparison (still in the southwest
quadrant), however it still remained far above
acceptable thresholds.
3.6 Conclusions of the ERG Report
Based on the MM-003 trial, POM appeared to extend OS
and PFS in comparison with HiDEX in a heavily treated
population who were refractory to BOR and LEN. The AE
profile appears to be manageable with appropriate dose
reductions and interruptions. The ERG drew attention to
these AEs occurring more frequently in the POM arm,
notably neutropenia.
For the comparison with BEN, the company used
covariate adjustment methods to adjust for the differences
between studies in patient characteristics. The covariate-
adjusted results were very similar to the unadjusted results
in terms of both PFS and OS, indicating that the differences
between studies in the selected covariates (patient charac-
teristics) have relatively little impact on the outcomes
observed. However, the selection of different datasets for
POM ? LoDEX seemed to alter the results for OS and
PFS.
For the comparison with PANO ? BOR ? DEX, the
POM ? LoDEX arms of a subpopulation from the MM-
002, MM-003 and MM-010 studies were compared with
the PANO ? BOR ? DEX arm of the PANORAMA-2
study using the MAIC method, which resulted in a 1-month
increase in median OS for patients receiving POM ?
LoDEX compared with the unweighted analysis. In both
cases, the median OS was shorter than those patients
receiving PANO ? BOR ? DEX. The hazard of death
seemed to be reduced by a similar amount for patients
receiving PANO ? BOR ? DEX compared with POM ?
LoDEX (in both MAIC weighted and unweighted analysis,
HR was approximately 0.75).
The economic model described in the CS was consid-
ered by the ERG to meet the NICE reference case to a
reasonable extent and was mostly in line with the decision
problem specified in the scope. The submitted model
included some errors and the ERG corrected the model and
conducted some exploratory analyses based on the pooled
MM-002, MM-003, MM-010 and all BTD trials dataset.
The full incremental exploratory analysis revealed that CC,
POM ? LoDEX and PANO ? BOR ? DEX were on the
cost-effectiveness frontier and BTD was either dominated
by CC or extendedly dominated by POM ? LoDEX.
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When POM ? LoDEX was compared with CC and
BTD, it can be considered as satisfying the end-of-life
criteria, but when compared with PANO ? BOR ? DEX,
the end-of-life criteria did not hold. The pairwise com-
parisons on the corrected company base-case revealed that
the ICERs of POM ? LoDEX versus CC and BTD were
both below the £50,000 threshold. The ICER of POM?-
LoDEX versus PANO ? BOR ? DEX showed that POM
? LoDEX was less effective but less costly, and the sav-
ings per QALY lost for POM ? LoDEX suggested it was
cost effective, without applying the end-of-life criteria
threshold. Various scenario analyses revealed that the
ICER is relatively robust against changes in input values
and assumptions.
3.6.1 Key Methodological Issues
Due to the lack of randomized evidence, the company used
different data sources and methodological approaches to
assess the comparative effectiveness of POM ? LoDEX
versus BTD and PANO ? BOR ? DEX. Even though the
chosen methods were deemed to be appropriate, the ERG
noted that there was no formal method selection process.
For instance, no justification was given by the company as
to why MAIC was chosen instead of other alternatives such
as simulated treatment comparison. Furthermore, the ERG
was concerned that there was no assessment for possible
unobserved confounding, which might have added addi-
tional uncertainty on the clinical and cost-effectiveness
estimates. Finally, the ERG identified some inconsistencies
in the implementation of these methods; for instance, CGP
and the mean covariate methods assumed different baseline
characteristics, or the indirect use of unrelated data from
the BTD trials in the POM ? LoDEX versus PANO ?
BOR ? DEX comparison, etc. Therefore, the ERG has the
opinion that a more systematic approach could have been
followed in choosing and applying these methods for the
analysis of nonrandomized observational data (e.g. in line
with the recommendations in NICE DSU TSD 17 and TSD
18 [34]).
The lack of a full incremental analysis including all
comparators in the CS was another concern. Instead of a
full incremental analysis, the company provided individual
comparisons and each of the comparisons was conducted
on a different dataset, which implied a slightly different
population for each of the comparisons. The ERG was
aware that a full incremental analysis would break the
randomization link between POM ? LoDEX and CC,
however considered that the additional insights gained
from full incremental analyses should not be dismissed.
4 National Institute for Health and Care
Excellence Guidance
The committee concluded that the appropriate positioning
of POM ? LoDEX, in line with clinical practice and the
evidence base, was after third or subsequent relapses, and
the relevant comparators were PANO ? BOR ? DEX, BTD
and CC. The committee acknowledged that the indirect
comparisons were associated with considerable uncertainty,
but recognised that the company had presented all the
appropriate evidence available for its decision making.
The committee agreed that the model structure was
appropriate. The ICERs varied based on the clinical data-
sets included, and using crossover adjustment and covariate
adjustment methods. The committee understood the full
incremental analyses provided by the ERG, but concluded
that it would base its decisions on the company’s base-case
ICERs, corrected by the ERG for errors, for the sake of not
breaking the randomisation between the POM ? LoDEX
and CC comparison.
The most plausible ICERs for POM ? LoDEX versus
CC and BTD were below £50,000 per QALY gained, and
Table 9 Results from the full incremental exploratory analyses
First full incremental analysis
(CGP method, ITT OS HR from
MM-003)
Second full incremental analysis (CGP
method, two-stage crossover-adjusted OS
HR from MM-003)
Third full incremental analysis (mean covariate
method, two-stage crossover-adjusted OS HR
from MM-003)
PANO ?
BOR ?
DEX
£142,930 per QALY gained £142,930 per QALY gained £146,307 per QALY gained
POM ?
LoDEX
£81,209 per QALY gained £57,288 per QALY gained £84,091 per QALY gained
BTD Dominated by CC Extendedly dominated by POM ? LoDEX Dominated by CC
CC – – –
POM pomalidomide, LoDEX low-dose dexamethasone, PANO panobinostat, BOR bortezomib, DEX dexamethasone, OS overall survival, BTD
bendamustine ? thalidomide ? dexamethasone, CGP corrected group prognostics, CC conventional chemotherapy, HR hazard ratio, ITT
intention to treat, QALY quality-adjusted life-year
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the committee concluded that POM meets the end-of-life
criteria compared with these two comparators. The end-of-
life criterion for an additional 3 months survival gain was
not met for the comparison with PANO ? BOR ? DEX,
and, after incorporating all PAS prices, the ICERs reflected
‘savings per QALY lost’, i.e. POM ? LoDEX was less
effective but less costly. The committee concluded that the
savings per QALY lost for POM ? LoDEX compared with
PANO ? BOR ? DEX were high enough for it to be
considered a cost-effective use of NHS resources without
applying the end-of-life criteria.
4.1 Final Guidance
POM ? LoDEX was recommended as an option for
treating multiple myeloma in adults at third or subsequent
relapse, i.e. after three previous treatments, including both
LEN and BOR, only when the company provided POM
with the discount agreed in the PAS.
5 Conclusions
In the absence of randomized evidence, alternative data
sources (including non-randomized evidence) can be used
to assess comparative effectiveness and to inform cost-ef-
fectiveness analyses. However, adjustment methods are
needed to account for the differences between patient
populations at baseline. This STA showed that the selection
of the method and its implementation can have quite an
impact on the ICER; therefore, it is important to base all of
these decisions on a systematic approach.
This STA also showed that a full incremental analysis
based on a common dataset for all comparisons might
provide additional insights (e.g. the treatments that were on
the cost-effectiveness frontier) compared with the indi-
vidual comparisons based on different datasets, which led
to different cost and QALY outcomes for the same treat-
ment (POM ? LoDEX) in each comparison. However, the
full incremental analysis in this STA required the break-
down of the randomisation between POM ? LoDEX and
CC, and the decision makers might prefer their decision to
be based on direct head-to-head evidence rather than
indirect evidence.
Another interesting outcome of this STA was the fact
that an intervention might satisfy the end-of-life criteria for
some of the comparators, whereas for others, it might not
since it leads to a lower total QALY outcome. In such a
situation, the decision maker can still recommend the
treatment if the ‘costs per QALY gained’ were below the
end-of-life threshold for the comparisons with less effec-
tive comparators, and if the ‘costs saved per QALY lost’
were higher than the standard threshold for the compar-
isons with more effective comparators.
Finally, this STA showed that a negative treatment
recommendation from a previous appraisal can be changed
in the presence of additional evidence, changes in the
clinical landscape, and in the costs and drug prices.
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